Correlation of Quality Measures with Estimates of Treatment Effect in Meta-analyses of Randomized Controlled Trials
Overview
Authors
Affiliations
Context: Specific features of trial quality may be associated with exaggeration or shrinking of the observed treatment effect in randomized studies. Therefore, assessment of trial quality is often used in meta-analysis. However, the degree to which specific quality measures are associated with treatment effects has not been well established across a broad range of clinical areas.
Objective: To determine if quality measures are associated with treatment effect size in randomized controlled trials (RCTs).
Design: Quality measures from published quality assessment scales were evaluated in RCTs included in meta-analyses from 4 medical areas (cardiovascular disease, infectious disease, pediatrics, and surgery). Included meta-analyses incorporated at least 6 RCTs, examined dichotomous outcomes, and demonstrated significant between-study heterogeneity in the odds ratio (OR) scale.
Main Outcome Measures: Relative ORs comparing overall treatment effect (summary OR) of high vs low-quality studies, as determined by each quality measure, with relative ORs less than 1 indicating larger treatment effect in low-quality studies.
Results: Twenty-four quality measures were analyzed for 276 RCTs from 26 meta-analyses. Relative ORs of high vs low-quality studies for these quality measures ranged from 0.83 to 1.26; none was statistically significantly associated with treatment effect. The proportion of studies fulfilling specific quality measures varied widely in the 4 medical areas. In analyses limited to specific medical areas, placebo control, multicenter studies, study country, caregiver blinding, and statistical methods were significantly associated with treatment effect on 7 occasions. These relative ORs ranged from 0.40 to 1.74. However, the directions of these associations were not consistent.
Conclusions: Individual quality measures are not reliably associated with the strength of treatment effect across studies and medical areas. Although use of specific quality measures may be appropriate in specific well-defined areas in which there is pertinent evidence, findings of associations with treatment effect cannot be generalized to all clinical areas or meta-analyses.
Agarwal A, Bala M, Zeraatkar D, Valli C, Alonso-Coello P, Ghosh N BMJ Nutr Prev Health. 2025; 7(2):e000833.
PMID: 39882286 PMC: 11773643. DOI: 10.1136/bmjnph-2023-000833.
Sultan M, Nawaz F, Alattar B, Khalaf E, Shadan S, El-Abiary N BMC Pediatr. 2025; 25(1):32.
PMID: 39810118 PMC: 11730125. DOI: 10.1186/s12887-024-05310-z.
Rui M, Hui Y, Mao J, Ma T, Zheng X Geriatr Orthop Surg Rehabil. 2024; 15:21514593241280912.
PMID: 39220251 PMC: 11365032. DOI: 10.1177/21514593241280912.
Quality of reporting inflammatory bowel disease randomised controlled trials: a systematic review.
Gordon M, Khudr J, Sinopoulou V, Lakunina S, Rane A, Akobeng A BMJ Open Gastroenterol. 2024; 11(1).
PMID: 38631808 PMC: 11033348. DOI: 10.1136/bmjgast-2023-001337.
Monti M, Beekman R, Spivak N, Thibaut A, Schnakers C, Whyte J Neurocrit Care. 2023; 40(1):51-57.
PMID: 38030874 PMC: 11495790. DOI: 10.1007/s12028-023-01873-4.